Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409

Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene besadenovec (CAN-2409) in patients with advanced non-small cell lung cancer (NSCLC) who had previously shown an inadequate response to immune checkpoint inhibitors (ICIs). The additional 12 months of follow-up data indicate that 50% of the 46 patients in the per-protocol population remained alive at 24 months after treatment.